Uniting human and machine intelligence for drug discovery in IPF

Idiopathic Pulmonary Fibrosis (IPF) is a progressive and ultimately fatal lung disease. A collaboration between AstraZeneca and BenevolentAI is leveraging scientific expertise and machine learning to develop novel targets to possibly treat IPF in the future. Listen to the experts from AstraZeneca and BenevolentAI talk about their collaboration in IPF, the challenges with traditional target discovery and how vast datasets and knowledge graphs are unlocking targets which were previously impossible to find. -------------------------------------------------------------------- Global site: https://www.astrazeneca.com/ Careers site: https://careers.astrazeneca.com/ Follow us: Twitter:   / astrazeneca   LinkedIn:   / astrazeneca   Instagram:   / astrazeneca   Facebook:   / astrazeneca